List of Excipients in Branded Drug AMIDATE(TM) ETOMIDATE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
HF Acquisition Co LLC DBA HealthFirst	AMIDATE(TM) ETOMIDATE	amidate(tm) etomidate	51662-1455	PROPYLENE GLYCOL
HF Acquisition Co LLC DBA HealthFirst	AMIDATE(TM) ETOMIDATE	amidate(tm) etomidate	51662-1455	WATER
HF Acquisition Co LLC DBA HealthFirst	AMIDATE(TM) ETOMIDATE	amidate(tm) etomidate	51662-1459	PROPYLENE GLYCOL
HF Acquisition Co LLC DBA HealthFirst	AMIDATE(TM) ETOMIDATE	amidate(tm) etomidate	51662-1459	WATER

AMIDATE Etomidate Excipient Strategy and Commercial Opportunities

Last updated: August 2, 2026

AMIDATE, the original etomidate injection brand, is a mature intravenous anesthetic product with limited traditional patent protection and substantial generic competition. Its commercial value is concentrated in formulation differentiation. The principal opportunity is to reduce or remove the high propylene glycol load used in conventional etomidate injection while preserving rapid onset, hemodynamic stability, shelf life, and compatibility with emergency-use workflows.

The strongest development paths are lipid emulsions, aqueous solubilized systems, cyclodextrin complexes, and ready-to-use presentations. Each path creates a different regulatory and patent profile. A lower-pain, lower-toxicity formulation could compete in anesthesia, emergency medicine, procedural sedation, and hospital stockpiles, but the product would need to address etomidate’s known adrenal suppression risk and establish a clear clinical or operational advantage over generic etomidate injection.

What is AMIDATE etomidate injection?

AMIDATE is etomidate injection, USP, an intravenous general anesthetic used primarily for induction of anesthesia. Etomidate is an imidazole-derived anesthetic with rapid onset and relatively limited cardiovascular depression compared with several alternative induction agents.

The conventional formulation contains:

Product attribute	Conventional AMIDATE-type formulation
Active ingredient	Etomidate
Strength	2 mg/mL
Route	Intravenous
Primary excipient	Propylene glycol
Propylene glycol concentration	Approximately 35% v/v in labeled conventional products
Preservative	Product-specific; conventional single-dose products generally do not rely on antimicrobial preservation
Main formulation issue	Injection pain and high cosolvent exposure
Main clinical limitation	Adrenal corticosteroid suppression after administration

The FDA-approved labeling identifies etomidate injection as an induction agent for general anesthesia. It is not intended to provide analgesia and is generally administered as a single induction dose rather than for prolonged infusion because of adrenal suppression concerns (FDA, 2017).

What excipients are used in AMIDATE and generic etomidate injection?

Propylene glycol is the central excipient in conventional etomidate injection. Etomidate has limited water solubility, so the cosolvent permits a clear injectable solution at the commercial 2 mg/mL strength.

The excipient profile creates several product-development constraints:

1. Propylene glycol can contribute to injection-site pain.
2. High systemic exposure may create toxicity concerns in patients receiving repeated or high-volume administration.
3. The formulation must remain sterile, chemically stable, and compatible with intravenous administration.
4. A replacement excipient must preserve etomidate solubility without causing hemolysis, precipitation, hypersensitivity, or unacceptable osmolality.
5. The product must remain practical for rapid administration in operating rooms and emergency departments.

A reformulated product should not treat propylene glycol removal as the sole objective. The commercial target is a clinically useful formulation with a measurable benefit, such as reduced injection pain, lower excipient burden, improved storage, fewer preparation steps, or lower risk in vulnerable patients.

What excipient strategies can replace propylene glycol?

Lipid emulsion formulations

A lipid emulsion can solubilize etomidate while reducing or eliminating propylene glycol. The most established precedent is the development of emulsion-based etomidate products designed to reduce injection pain and avoid the high cosolvent load associated with conventional formulations.

Potential excipients include:

• Soybean oil or other pharmaceutically acceptable oils
• Egg phospholipids or alternative phospholipid systems
• Glycerol for tonicity adjustment
• Water for injection
• pH-adjusting agents
• Nitrogen or other headspace controls where appropriate

The lipid-emulsion approach has several commercial advantages:

• It directly addresses the leading formulation complaint.
• It can support a differentiated 505(b)(2) development strategy in the United States.
• It provides a recognizable formulation platform for hospital anesthesiology.
• It may support reduced injection pain compared with conventional etomidate injection.

The principal risks are emulsion stability, droplet-size control, microbial control, container interaction, and the need to demonstrate physical stability during storage and administration. Lipid emulsions also introduce handling and compatibility requirements that do not apply to clear solutions.

Aqueous cosolvent systems

A second strategy uses alternative water-miscible solubilizers or a lower concentration of propylene glycol. Candidate excipients may include polyethylene glycol, ethanol in controlled concentrations, glycerol, or other injectable cosolvent systems.

This approach could preserve the operational simplicity of a clear solution. It may also reduce manufacturing complexity compared with an emulsion. The challenge is that many cosolvents carry their own tolerability and regulatory limitations. A formulation that replaces propylene glycol with another high-load cosolvent may have limited commercial value unless it produces a clear clinical or safety benefit.

The most credible aqueous strategy is a substantially reduced-cosolvent formulation with:

• Lower injection pain
• Lower osmolality or improved local tolerability
• Comparable etomidate exposure
• No new excipient-related safety signal
• At least two years of practical room-temperature stability

Cyclodextrin-complexed etomidate

Cyclodextrins can improve apparent aqueous solubility by forming inclusion complexes with lipophilic drug molecules. A cyclodextrin-based etomidate formulation could potentially provide a clear, low-cosolvent injection.

Relevant development variables include:

• Cyclodextrin type and substitution pattern
• Complexation efficiency
• Free versus complexed etomidate
• Renal elimination and tissue distribution
• Hemolysis and local tolerability
• Container compatibility
• Dose-volume requirements

Cyclodextrin systems may have stronger intellectual-property potential than a simple propylene glycol reduction because the claims can cover the drug-excipient complex, composition ranges, manufacturing process, and use in anesthesia. They also carry a greater clinical and regulatory burden because the excipient may materially affect pharmacokinetics and tissue exposure.

Nanoemulsion and advanced dispersion systems

Nanoemulsions, submicron emulsions, and other colloidal systems could offer rapid drug release with reduced injection pain. These technologies may support patent claims covering droplet size, emulsifier ratios, manufacturing conditions, and stability specifications.

Their commercial value depends on whether the formulation produces a meaningful benefit over a conventional lipid emulsion. A complex delivery system with no clear improvement may increase manufacturing and regulatory costs without creating pricing power.

Ready-to-use and device-integrated presentations

Excipient innovation can be combined with presentation innovation. Opportunities include:

• Prefilled syringes
• Unit-dose cartridges
• Polymer-compatible emergency syringes
• Low-dead-volume presentations
• Barcoded anesthesia trays
• Ready-to-administer kits for rapid sequence intubation

These products may not require a new active-ingredient patent. Commercial protection can instead arise from formulation patents, device patents, packaging patents, trade secrets, and hospital purchasing contracts.

What patents protect AMIDATE etomidate?

AMIDATE is a legacy product. Its original composition and product patents are expected to be expired or commercially irrelevant in the United States. The commercial freedom-to-operate analysis should therefore focus on newer formulation and delivery patents rather than the original AMIDATE brand.

IP category	Relevance to AMIDATE etomidate
Original etomidate compound patents	Generally expired for a product introduced decades ago
Conventional propylene glycol formulation	Likely vulnerable to generic competition
Lipid-emulsion formulations	Potentially protectable through composition and process claims
Cyclodextrin formulations	Potential composition, complexation, and method claims
Nanoemulsions	Potential droplet-size, process, and stability claims
Prefilled syringes	Device and container-closure protection
Method-of-use claims	Possible claims for reduced injection pain or selected patient populations
Manufacturing methods	Potential trade-secret and patent protection
Brand AMIDATE trademark	Brand protection does not block generic etomidate entry

The relevant U.S. regulatory reference is the FDA Orange Book. Listed patents and exclusivity must be assessed at the product level because a legacy brand name does not establish current patent protection. The FDA Orange Book also distinguishes between listed patents, regulatory exclusivity, and marketing status (FDA, 2025a).

When does AMIDATE lose exclusivity?

AMIDATE’s practical exclusivity has already ended. Etomidate is a mature small-molecule anesthetic with multiple generic products and no meaningful remaining new-drug exclusivity associated with the original brand.

The commercial timeline is therefore different from a protected branded product:

Exclusivity element	AMIDATE etomidate status
New chemical entity exclusivity	Expired
Orphan-drug exclusivity	Not applicable
Pediatric exclusivity	No current commercial significance identified
Original compound patent	Expected expired
Formulation patent opportunity	Available only for newly developed formulations
Generic competition	Established
Paragraph IV risk	Relevant mainly to future listed formulation patents
Biosimilar risk	Not applicable

A new etomidate formulation could obtain approval through an NDA, including a potential 505(b)(2) pathway where the applicant relies partly on existing FDA findings for etomidate. The product would need to establish formulation-specific safety, pharmacokinetic performance, and manufacturing controls. A 505(b)(2) approval does not automatically provide broad exclusivity against all generic etomidate products.

What is the Orange Book status of AMIDATE?

The Orange Book status must be evaluated using the current FDA listing, product number, and marketing status. Legacy AMIDATE listings may not reflect active commercial marketing by the original sponsor. The critical business question is whether any unexpired patent is currently listed against the reference product and whether an approved generic product is therapeutically equivalent.

For a new formulation, Orange Book listing may become strategically important if the applicant receives an approved NDA and obtains patents that claim the approved formulation, method of use, or delivery system. A listed patent can create a Paragraph IV litigation trigger when a generic applicant seeks approval before patent expiration.

The strongest Orange Book strategy would involve narrow, commercially essential claims covering:

• Exact excipient ratios
• Particle or droplet-size limits
• pH and osmolality ranges
• Stability after dilution
• Container-closure configuration
• A clinically differentiated method of administration

Broad claims that merely recite etomidate plus a conventional injectable excipient are more vulnerable to invalidity and obviousness attacks.

Which companies are challenging AMIDATE?

Generic manufacturers have challenged the commercial position of legacy etomidate brands through ANDA approvals and hospital supply competition rather than through highly visible brand litigation. Etomidate injection is supplied by multiple generic and institutional manufacturers, including large injectable-drug companies and contract manufacturers.

The competitive set typically includes products marketed under labels such as:

• Etomidate injection, USP
• Generic etomidate 2 mg/mL
• Single-dose vial presentations
• Multiple vial sizes for anesthesia and emergency use

A specific Paragraph IV challenge to a legacy AMIDATE formulation is unlikely to be the principal market issue because the underlying product is mature and genericized. Litigation risk becomes more relevant for a newly approved propylene glycol-free or device-integrated formulation.

What commercial opportunities exist for an improved etomidate formulation?

Reduced injection pain

Injection pain is the clearest formulation-led opportunity. A product that demonstrates lower pain scores in controlled clinical studies could obtain preference in induction settings, particularly where patient comfort and rapid administration matter.

The evidence should compare the new product directly with conventional etomidate injection at equivalent etomidate doses. A formulation claim based only on excipient reduction is weaker than a product supported by statistically and clinically meaningful tolerability data.

Emergency medicine and rapid sequence intubation

Etomidate is widely used in emergency airway management because of its rapid onset and relative cardiovascular stability. A ready-to-use formulation could target:

• Emergency departments
• Ambulance services
• Intensive-care units
• Military and disaster-response systems
• Community hospitals with limited pharmacy staffing

The product must tolerate rapid handling, temperature variation within labeled limits, and administration through commonly used intravenous systems.

Anesthesia departments

Anesthesia departments may value a formulation that reduces injection pain, simplifies drug preparation, and minimizes waste. Prefilled syringes and unit-dose packaging could support premium pricing if they reduce preparation time and medication-error risk.

Pediatric and geriatric use

These populations may create opportunities for lower-volume presentations and improved tolerability. Claims should be based on actual clinical data. Pediatric positioning would require age-appropriate dosing, excipient exposure analysis, and supporting FDA evidence.

Hospital supply resilience

Sterile injectable shortages create a commercial opening for second-source manufacturing. A formulation with a robust supply chain for drug substance, lipid components, vial systems, and sterile filling could compete even without a major clinical innovation.

How does etomidate compare with competing induction agents?

Attribute	Etomidate	Propofol	Ketamine
Onset	Rapid	Rapid	Rapid
Cardiovascular depression	Generally limited	More pronounced in vulnerable patients	Often supports blood pressure
Analgesia	No	No	Yes
Injection pain	Common with conventional formulation	Common, formulation-dependent	Variable
Adrenal suppression	Important limitation	Not the principal limitation	Not the principal limitation
Formulation opportunity	Propylene glycol removal, emulsion, device	Emulsion and preservative systems	Concentration, formulation, device
Primary commercial positioning	Hemodynamically sensitive induction and RSI	Routine induction and procedural anesthesia	RSI, analgesia, dissociative sedation

Etomidate’s formulation opportunity is strongest where cardiovascular stability is valued and injection pain or excipient burden is a purchasing concern. A new product would compete against clinical familiarity and generic pricing, not only against other branded anesthetics.

What generic entry risks exist for a new AMIDATE formulation?

A new etomidate formulation faces five principal generic-entry risks:

1. A generic applicant may copy the formulation after patent expiry.
2. Narrow excipient claims may be designed around.
3. A formulation patent may fail for obviousness if the excipient substitution is predictable.
4. A generic could use the same active ingredient with a different excipient and rely on a separate approval pathway.
5. Hospital buyers may treat all 2 mg/mL etomidate products as substitutable unless the new formulation has a documented clinical advantage.

Patent protection should therefore combine composition claims with manufacturing, packaging, stability, and method-of-use claims. The applicant should also evaluate whether the formulation can qualify for FDA product-specific exclusivity or a new clinical investigation period under the applicable 505(b)(2) framework.

How strong is the patent estate for a propylene glycol-free etomidate product?

A propylene glycol-free etomidate product can have a moderate-to-strong patent estate if the formulation uses a technically non-obvious excipient system and produces demonstrated clinical benefits.

Stronger claim categories

• Defined lipid composition and droplet-size distribution
• Specific cyclodextrin-to-etomidate ratios
• Stability after dilution or admixture
• Reduced injection-pain method claims
• Prefilled syringe and container-closure combinations
• Sterile manufacturing processes that control degradation products
• Formulations with defined osmolality and pH ranges

Weaker claim categories

• Etomidate with a generic injectable cosolvent
• Broad claims covering any non-propylene-glycol formulation
• Claims based solely on theoretical reduction in pain
• Claims that lack comparative clinical evidence
• Claims that read on common prior-art emulsions

Trade-secret protection should cover homogenization parameters, hold times, nitrogenation, sterile filtration decisions, and filling conditions. These controls can remain valuable even after composition patents expire.

What licensing deals could support AMIDATE reformulation?

A reformulation program could use licensing in four areas:

• Etomidate drug substance supply
• Lipid-emulsion or cyclodextrin technology
• Prefilled syringe and drug-device systems
• Contract sterile manufacturing

The most valuable deal structure would combine formulation rights with clinical and regulatory support. A license limited to a generic excipient platform may provide little differentiation unless the licensor also controls process know-how or issued patents.

Potential counterparties include injectable-drug companies, anesthesia-product specialists, hospital supply manufacturers, and platform technology companies with approved parenteral delivery systems. Any license should address field of use, geographic rights, manufacturing rights, improvement ownership, patent prosecution, and shortage-related supply obligations.

What FDA regulatory pathway applies to a new AMIDATE formulation?

A new formulation would likely require an NDA pathway, potentially under section 505(b)(2), depending on the extent of reliance on existing etomidate safety and efficacy findings. The development program would normally address:

• Drug product quality and sterility
• Excipient qualification
• Pharmacokinetic comparability
• Local tolerability and injection pain
• Hemodynamic effects
• Adrenal suppression
• Compatibility with infusion and administration materials
• Container-closure integrity
• Extractables and leachables
• Stability under labeled storage conditions

FDA guidance for 505(b)(2) applications emphasizes the need to identify reliance on listed drugs and address differences that could affect safety or effectiveness (FDA, 2023). A formulation that changes the rate of release, distribution, or exposure may require more than a simple bridging study.

Key Takeaways

• AMIDATE is a legacy etomidate brand with expired practical exclusivity and established generic competition.
• Conventional etomidate injection relies on approximately 35% propylene glycol, creating the main excipient-led differentiation opportunity.
• Lipid emulsions are the most commercially credible propylene glycol-reduction strategy.
• Cyclodextrin and advanced dispersion systems may create stronger patent positions but carry greater development risk.
• A new product should combine formulation innovation with prefilled delivery, reduced preparation steps, or improved injection tolerability.
• The principal regulatory route is likely an NDA, potentially using the 505(b)(2) pathway.
• Patent protection should cover composition, process, stability, device, and clinically supported method-of-use claims.
• Biosimilar competition is not relevant because etomidate is a small molecule. Generic ANDA competition is the primary market risk.
• The best commercial targets are emergency airway management, anesthesia departments, intensive-care units, and hospital systems seeking sterile-injectable supply resilience.

FAQs About AMIDATE Etomidate Excipient Strategy

Is propylene glycol necessary in etomidate injection?

No. Propylene glycol is used to solubilize etomidate in conventional clear injectable formulations, but alternative systems such as lipid emulsions and cyclodextrin complexes can reduce or eliminate it.

Can a propylene glycol-free etomidate product receive new patent protection?

Yes. Patent protection may be available for a non-obvious composition, excipient ratio, manufacturing process, stability profile, device, or clinically supported administration method. The original etomidate molecule itself is not the likely source of new exclusivity.

Is AMIDATE still protected by FDA exclusivity?

No meaningful original-product exclusivity remains for legacy AMIDATE. Any current commercial protection would depend on active patents, trademarks, supply contracts, or a newly approved differentiated formulation.

Does etomidate have biosimilar risk?

No. Etomidate is a chemically synthesized small molecule. Competitors enter through generic-drug pathways rather than biosimilar pathways.

What is the highest-value formulation opportunity for etomidate?

A ready-to-use, propylene glycol-free lipid-emulsion formulation with demonstrated reduction in injection pain, stable room-temperature storage, and compatibility with emergency-use administration has the clearest commercial positioning.

References

1. U.S. Food and Drug Administration. (2017). Etomidate injection, USP prescribing information. FDA.

2. U.S. Food and Drug Administration. (2023). Applications covered by section 505(b)(2). FDA.

3. U.S. Food and Drug Administration. (2025a). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. U.S. Food and Drug Administration. (2025b). Drugs@FDA: FDA-approved drugs database. FDA.

5. DailyMed. (2025). Etomidate injection prescribing information. National Library of Medicine.